Compare Gilead Sciences, Inc. (GILD) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Sea Limited — how do they compare? Gilead Sciences, Inc. trades at $133.55 (market cap $163.51B), while Sea Limited trades at $106.46 (market cap $68.21B). The key difference: Gilead Sciences, Inc. is far larger — about 2.4× Sea Limited's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Sea Limited pays none. Which is the better fit depends on your goals.
| GILD | SE | |
|---|---|---|
Market Cap | $163.51B | $68.21B |
Sector | Health | Media |
52-Week High | $155.80 | $196.50 |
52-Week Low | $108.22 | $78.16 |
Enterprise Value | $178.05B | $61.25B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Sea Limited (SE) trades at $107.47, down 1.67% on the day, with a bullish technical outlook supported by moving averages and strong cash flow growth. Revenue surged to $22.94 billion in 2025, with net income reaching $1.58 billion, though recent earnings misses in Q3 and Q4 2025 temper momentum. Analyst sentiment remains optimistic with a $131 consensus price target, but insider selling and high valuation ratios pose caution.
The stock offers growth potential from expanding Southeast Asian digital services, but risks include competitive pressures and earnings volatility. With a P/E of 43.84, valuation is steep relative to peers, requiring sustained execution to justify upside. Investors should weigh robust fundamentals against near-term headwinds from insider transactions and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
